# Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

> **NCT01495572** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 5 (actual)

## Conditions studied

- Metastatic Melanoma
- Skin Cancer

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Aldesleukin
- **DRUG:** MART-1 Reactive CD8+ PBL

## Key facts

- **NCT ID:** NCT01495572
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Due to slow accrual, the investigator decided to close the study.
- **Last updated:** 2015-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01495572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01495572, "Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01495572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*